ReviewCurrent opinion in rheumatology2026
"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".
Review in Current opinion in rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewTo review and highlight key research findings in children and adults with chronic nonbacterial osteomyelitis (CNO). RECENT
findingsRecent studies highlight substantial progress in CNO. Emerging data supports the existence of distinct phenotypic clusters in children and adults, along with recognition of extraosseous manifestations associated with greater disease severity and biologic use. New EULAR/ACR classification criteria and expert consensus recommendations represent important progress toward improving patient care. Administrative data is promising for cohort building and epidemiologic research in CNO. Recent work has identified key health domains impacting patients, highlighting the multidimensional nature, and reduced quality of life in CNO. Genetic and biomarker studies provide insight into inflammatory pathways. Advances in imaging and disease activity assessment emphasize the limitations of clinical measures alone, with composite measures providing improved performance. Reports of sarcopenia, and bone microarchitecture abnormalities suggest additional information may be gleaned from imaging. Finally, expanded therapeutic options are being used in recalcitrant cases suggesting that targeting interleukin (IL)-17/IL-23/Janus kinase pathways need to be tested in controlled studies to determine their place in treatment of CNO. SUMMARY: There is encouraging progress in CNO, with research efforts expanding our understanding of this disease across the age spectrum, with the ultimate goal of improving patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.